Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$1.96 - $3.32 $33,908 - $57,436
17,300 Added 131.06%
30,500 $63,000
Q2 2022

Aug 15, 2022

BUY
$2.27 - $4.86 $25,651 - $54,918
11,300 Added 594.74%
13,200 $37,000
Q1 2022

May 16, 2022

BUY
$3.69 - $5.65 $7,011 - $10,735
1,900 New
1,900 $8,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Aquatic Capital Management LLC Portfolio

Follow Aquatic Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aquatic Capital Management LLC with notifications on news.